Germany's Plan To Foster And Grow Biopharma Innovation

By Suzanne Elvidge, Contributing Writer
Follow Me On Twitter @suzannewriter

In Germany, like many other developed markets, net growth in pharmaceuticals has slowed or is declining, according to 2018 figures from IQVIA. There has been a shift toward specialty pharmaceuticals, however. Specialty medicines represented 39 percent of spending in the 10 developed markets, with Germany as one of the major drivers. To ensure the continued growth of the industry, particularly the specialty pharmaceuticals industry, innovation needs to be encouraged and supported. This is the role of the bioclusters and technology parks across Germany.